<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02768337</url>
  </required_header>
  <id_info>
    <org_study_id>CamBMT1</org_study_id>
    <secondary_id>2013-002398-23</secondary_id>
    <secondary_id>1200.206</secondary_id>
    <secondary_id>146009</secondary_id>
    <nct_id>NCT02768337</nct_id>
  </id_info>
  <brief_title>Cambridge Brain Mets Trial 1</brief_title>
  <acronym>CamBMT1</acronym>
  <official_title>Cambridge Brain Mets Trial 1: A Proof-of-principle Phase 1b/Randomised Phase 2 Study of Afatinib Penetration Into Cerebral Metastases for Patients Undergoing Neurosurgical Resection, Both With and Without Prior Low-dose, Targeted Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Brain Tumour Charity</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cambridge University Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral
      metastases for patients undergoing neurosurgical resection, both with and without prior
      low-dose, targeted radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Brain metastases occur in 20-40% of all patients with cancer, with an incidence 10 times
      higher than that of primary malignant brain tumours. patients with brain metastases are an
      underserved population. Overall they have a poor prognosis with a median survival of 1-2
      months with corticosteroids and only 5-7 months after whole brain radiotherapy. An important
      factor in the poor prognosis of patients with brain metastases is the inability of many drugs
      to penetrate the blood-brain-barrier into tumour tissue.Combination therapy with surgical
      excision, radiotherapy and novel drugs could potentially improve the prognosis for some
      patients.

      CamBMT1 is an open label, 3 Arm randomised Phase 2 trial investigating whether administration
      of a low dose of targeted radiotherapy during afatinib treatment could increase the
      concentration of drug penetration into brain metastases.

      Eligible patients in Phase 2 will be randomised to 1 of 3 Arms:

      Arm 1: no radiotherapy Arm 2: 2Gy radiotherapy Arm 3: 4Gy radiotherapy All patients will also
      receive 11 days of afatinib treatment at the recommended Phase 2 dose, previously determined
      in a Phase 1b safety run-in phase.

      On Day 10, of afatinib treatment patients randomised to Arms 2 or 3 will receive their
      allocated dose of radiotherapy On Day 12, patients will undergo neurosurgical resection of
      their brain metastasis/ses.

      Patients will be followed up on Day 22-28 and on Day 41 +/- 7 days

      For the primary outcome measure, samples for measurement of plasma concentration of afatiinib
      will be taken pre-treatment, on day 10 and Day 12 post-resection. Tumour tissue from the
      resected brain metastasis will be taken on day 12 for measurement of afatinib concentration.
      The primary outcome measure is the ratio of these concentrations.

      The patient population studied will be breast/likely breast or lung/likely lung primary
      cancers with operable brain metastases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of afatinib concentration in: [resected brain metastases] / [plasma] - each measured in (ng/mL) on day 12</measure>
    <time_frame>Day 12 of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of afatinib alone and combined with targeted low-dose radiotherapy - assessed by number of participants with treatment- related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>From consent to Day 41+/-7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Brain Cancer</condition>
  <condition>Advanced Breast Cancer</condition>
  <condition>Advanced Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1: Afatinib only at Recommended Phase 2 dose (RP2D)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No targeted radiotherapy. Afatinib at Recommended Phase 2 Dose for 11 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 2 Gy on Day 10 of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will receive the RP2D of afatinib for 11 days and will receive targeted radiotherapy at a dose level of 4 Gy on Day 10 of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <arm_group_label>Arm 1: Afatinib only at Recommended Phase 2 dose (RP2D)</arm_group_label>
    <arm_group_label>Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy</arm_group_label>
    <arm_group_label>Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy</arm_group_label>
    <other_name>Giotrif</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>2 Gy targeted radiotherapy</intervention_name>
    <arm_group_label>Arm 2: Afatinib RP2D + 2 Gy targeted radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>4 Gy targeted radiotherapy</intervention_name>
    <arm_group_label>Arm 3: Afatinib RP2D + 4 Gy targeted radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Operable brain metastases from likely breast or lung origin as determined by local
             MDT. Both of the following groups of patients may be considered eligible:

               1. Patients with a past history of histologically/cytologically confirmed breast or
                  lung cancer, now presenting with a new likely brain metastasis from that primary.

               2. Patients presenting with new, primary (breast/lung) tumours, plus synchronous,
                  operable brain metastases, without pre-op tissue diagnosis.

          -  ECOG performance score 0, 1 or 2.

          -  Aged 18 years or older.

          -  Written informed consent.

          -  Patients are allowed to take oral corticosteroids however the plan should be for them
             to receive a stable dose of corticosteroids for at least 3 days before neurosurgery
             (i.e. trial days 10, 11, 12)

        Exclusion Criteria

        The presence of any of the following will preclude patient inclusion:

          -  History or presence of existing interstitial lung disease.

          -  Current clinically significant impairment of cardiac function (greater than Class II
             according to New York Heart Association [NYHA] classification).

          -  Unstable ischemic heart disease within the last 6 months, including myocardial
             infarction.

          -  Presence of QTc interval prolongation &gt;480 ms.

          -  Clinically significant corneal or conjunctival eye disease.

          -  Clinically significant skin diseases such as psoriasis, rash or atopic dermatitis.

          -  Clinically significant impairment of GI function or GI disease including total
             gastrectomy that may alter the absorption of afatinib.

          -  Clinically significant, active peptic ulcer disease.

          -  Known positive test for human immunodeficiency virus (HIV), hepatitis B surface
             antigen (HBsAg) or hepatitis C virus (HCV) antibody or patients with any untreated
             serious infections.

          -  Pregnancy and contraception:

        Female patients of child bearing potential must have a negative serum or urine pregnancy
        test within 14 days prior to registration/randomisation, and must use an effective method
        of contraception at least 1 week prior to treatment, during treatment and for at least 28
        days after the final dose of study drug. Acceptable methods are:

        True abstinence (this must be the patients usual and preferred lifestyle, not just for the
        duration of the study) Oral contraceptive (either combined or progestogen alone)
        Contraceptive implant, injections or patches Vaginal ring Intrauterine device (IUD, coil or
        intrauterine system) Condom and cap Diaphragm plus spermicide Tubal Ligation

          -  A female patient of child bearing potential is defined as a sexually mature woman not
             surgically sterilized or not post-menopausal for at least 24 consecutive months if
             aged 55 years or younger or 12 months if aged 56 years or older.

          -  Men must use one of the following, reliable forms to contraception for the entire
             duration of treatment and for 28 days after the final dose of study drug:

        Condom plus spermicide even if female partner is using another method of contraception (Men
        should also use a condom to protect male partners, or female partners who are pregnant or
        breast feeding, from exposure to the study medicine in semen).

        True abstinence (this must be the patients usual and preferred lifestyle, not just for the
        duration of the study)

          -  Concurrent severe and/or uncontrolled medical conditions (due to concurrent disease
             other than cancer) which in the opinion of the investigator could compromise
             participation in the study.

          -  Known or suspected active drug or alcohol abuse.

          -  Administration of chemotherapy, immunotherapy, radiotherapy, hormonal therapy or any
             investigational cancer therapy within 5 half-lives of the prior therapy, or 2 weeks of
             first dose of afatinib, whichever is longer.

          -  Known hypersensitivity to afatinib or its excipients.

          -  Toxicities of prior therapies that have not resolved to â‰¤CTCAE Grade 1.

          -  Any of the following laboratory test findings:

        Haemoglobin &lt;90 g/L Absolute neutrophil count &lt;1 x 109 /L Platelet count &lt;100 x 109 /L AST
        or ALT &gt;2.5 x upper limit of normal range (ULN) Total serum bilirubin &gt;1.5 x ULN Creatinine
        &gt;1.5 x ULN Creatinine clearance &lt;30mL/min (Cockcroft-Gault)

          -  Patients taking potent P-gp inducers/inhibitors (see section 15.9)

          -  Any other reason which, in the opinion of the Investigator, interferes with the
             ability of the patient to participate in the study.

          -  Patients unable to comply with the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Baird, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicola Ramenatte</last_name>
    <phone>+44 1223 216083</phone>
    <email>cctu.cancer@addenbrookes.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 28, 2016</study_first_submitted>
  <study_first_submitted_qc>May 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2016</study_first_posted>
  <last_update_submitted>February 21, 2017</last_update_submitted>
  <last_update_submitted_qc>February 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cambridge University Hospitals NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Richard D. Baird MD PhD</investigator_full_name>
    <investigator_title>Dr Richard Baird</investigator_title>
  </responsible_party>
  <keyword>brain metastasis</keyword>
  <keyword>operable brain metastasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

